Facebook
  • Home page
  • About Us
  • Our Products
  • Careers
  • NewsRoom
  • Privacy Policy
  • Quality Policy
  • Communication with Costumers
  • العربية
  • Home page
  • About Us
  • Our Products
  • Careers
  • NewsRoom
  • Privacy Policy
  • Quality Policy
  • Communication with Costumers
  • العربية
Facebook
Home by Therapeutic Group Lipid lowering drugs

LOW-LIP

Low-lip
  • Low-lip

Product Information

COMPOSITION:

LOW-LIP 10 mg: Each film coated tablet contains: 10.845 mg Atorvastatin calcium 3 H2O equivalent to

10 mg Atorvastatin.

LOW-LIP 20 mg: Each film coated tablet contains: 21.69 mg Atorvastatin calcium 3 H2O equivalent to 20

mg Atorvastatin.

LOW-LIP 40 mg: Each film coated tablet contains: 43.385 mg Atorvastatin calcium 3 H2O equivalent to

40 mg Atorvastatin.

LOW-LIP 80 mg: Each film coated tablet contains: 86.76 mg Atorvastatin calcium 3 H2O equivalent to 80

mg Atorvastatin.

PHARMACOLOGICAL CLASSIFICATIONS

Lipid regulating drug.

INDICATIONS AND USAGE

LOW-LIP is indicated at significantly increased risk for atherosclerotic vascular disease due to

hypercholesterolemia.

LOW-LIP is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and

cholesterol and other nonpharmacologic measures alone has been inadequate.

LOW-LIP can be started simultaneously with diet in patients with CHD or multiple risk factors for CHD.

Prevention of Cardiovascular Disease:

– In patients without clinically evident coronary heart disease, but with multiple risk factors for coronary

heart disease such as age, smoking, low HDL-C, hypertension or a family history of early coronary heart

disease, LOW-LIP is indicated to:

  • Reduce the risk of myocardial infarction.
  • Reduce the risk of stroke.
  • Reduce the risk for revascularization procedures and angina.

– In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple

risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LOWLIP

is indicated to:

  • Reduce the risk of myocardial infarction
  • Reduce the risk of stroke

– In patients with clinically evident coronary heart disease, LOW-LIP is indicated to:

  • Reduce the risk of non-fatal myocardial infarction
  • Reduce the risk of fatal and non-fatal stroke
  • Reduce the risk for revascularization procedures
  • Reduce the risk of hospitalization for CHF
  • Reduce the risk of angina

LOW-LIP is also indicated in cases of Hyperlipidemia.

 

DOSAGE AND ADMINISTRATION

Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types

IIa and IIb):

The recommended starting dose of LOW-LIP is 10 or 20 mg once daily.

Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily.

The dosage range of LOW-LIP is 10 to 80 mg once daily.

LOW-LIP can be administered as a single dose at any time of the day, with or without food.

The starting dose and maintenance doses of LOW-LIP should be individualized according to patient

characteristics such as goal of therapy and response. After initiation and/or upon titration of LOW-LIP, lipid

levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.

Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 – 17 years of age)

The recommended starting dose of LOW-LIP is 10 mg/day; the maximum recommended dose is 20 mg/day.

Doses should be individualized according to the recommended goal of therapy and adjustments should be

made at intervals of 4 weeks or more.

Homozygous Familial Hypercholesterolemia

The dosage of LOW-LIP in patients with homozygous FH is 10 to 80 mg daily. LOW-LIP should be used as

an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments

are unavailable.

In Patients with Renal Impairment

Renal disease does not affect the plasma concentrations or LDL-C reduction of LOW-LIP; thus, dosage

adjustment in patients with renal dysfunction is not necessary.

Concomitant Lipid-Lowering Therapy

HOW SUPPLIED

Low-lip 10 mg: Pack of 10 film coated tablets.

Low-lip 10 mg: Pack of 20 film coated tablets.

Low-lip 10 mg: Pack of 30 film coated tablets.

Low-lip 20 mg: Pack of 10 film coated tablets.

Low-lip 20 mg: Pack of 30 film coated tablets.

Low-lip 40 mg: Pack of 10 film coated tablets.

Low-lip 40 mg: Pack of 20 film coated tablets.

Low-lip 80 mg: Pack of 10 film coated tablets.

Categories: Lipid lowering drugs, Tablets
Share:
AZITROLYD

Azitrolyd
Lukast
LUKAST

Related products

Amlodipine
Quick View Read more

AMLODIPINE ALFARES

Artral
Quick View Read more

ARTRAL

VASOLOL
Quick View Read more

VASOLOL

Losardipin Plus
Quick View Read more

LOSARDIPIN PLUS

Phone number

+963 11 584 2222

address

At-Tall District Syria, Sednayah Road، Mneen, Syria

e-mail

[email protected]

logo

Contact Us

  • 33070, Damascus, Syria
  • +963 11 584 2224
  • +963 11 584 2225
  • [email protected]
  • Saturday-Thursday 7:30 am - 3:30 pm

visit us

All Right Reseved . Alfares Pharmaceuticals 2021